INSUBCONTINENT EXCLUSIVE:
China’s cost and efficiency advantages in drug development have been recognised at the world’s largest cancer research conference in the
US, where companies were eagerly shopping for Chinese innovations, according to a new report.
Nearly a third of the presentations at the
American Society of Clinical Oncology’s annual meeting last month involved drug candidates from Chinese companies, American brokerage
Jefferies said on Monday in its “Shopping in China’s Biotech Supermarket” report
